Indeed, the oncogenic and tumor-suppressing functions of MKK3 were clearly dependent on the tumor type, suggesting that the evaluation of MKK3 as a potential molecular target in cancer therapy requires it to be contextualized with the organ affected by cancer disease. This evidence concerns the gene MAP2K3 and cancer.